{"id":2906,"date":"2026-11-15T02:22:51","date_gmt":"2026-11-15T02:22:51","guid":{"rendered":"https:\/\/clinicanering.com\/blog\/weight-loss\/mounjaro-long-term-safety\/"},"modified":"2026-11-15T02:22:51","modified_gmt":"2026-11-15T02:22:51","slug":"mounjaro-long-term-safety","status":"publish","type":"post","link":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/","title":{"rendered":"Is Mounjaro safe long term? Kidneys, liver and heart"},"content":{"rendered":"<blockquote>\n<p><strong>Main points<\/strong><\/p>\n<ul>\n<li>The longest study of <strong>tirzepatide<\/strong>, the active ingredient in <strong>Mounjaro<\/strong>, followed people with diabetes for about 4 years, and in it the drug did no harm to the kidneys or the heart.<\/li>\n<li>In the kidneys, <strong>tirzepatide<\/strong> reduced the loss of albumin in the urine and slowed the decline in function in people who already had kidney disease. The real risk to the kidneys is dehydration from severe vomiting or diarrhea.<\/li>\n<li>In the liver, it removed fat and calmed inflammation in a short study, but we still don&#8217;t know whether this prevents cirrhosis.<\/li>\n<li>The most complete review of the controlled studies found no increase in cancer with the injections in the <strong>GLP-1<\/strong> group, but these studies last only a few years and some cancers take longer to show up.<\/li>\n<li>We still lack data on use over decades and the heart results in people with obesity but no diabetes, which are being studied.<\/li>\n<\/ul>\n<\/blockquote>\n<p>In studies of up to four years, <strong>Mounjaro<\/strong> did no harm to the kidneys, the liver or the heart. For the kidneys and the heart, these data come from people with type 2 diabetes, and for the liver, from a one-year study. <strong>Tirzepatide<\/strong>, the active ingredient in <strong>Mounjaro<\/strong>, was approved in the United States in 2022, and nobody has data on people who took the drug for ten or twenty years, so the answer to whether <strong>Mounjaro<\/strong> is harmful in the long term holds only for that period. People who use the injection only to lose weight, without diabetes, have less kidney and heart data, and the large study done in this group ends in 2027. The problems that did appear came more from a lack of water in the body, from the gallbladder and from muscle lost along with the fat than from slow wear on the organs, which is what many people fear.<\/p>\n<p>This question carries more weight because obesity is a chronic disease and, when a person stops the injection, much of the weight comes back, as I showed when I wrote about <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/stopping-weight-loss-injections-does-weight-come-back\/\">stopping the weight-loss injection<\/a>. Many people who start <strong>Mounjaro<\/strong> today will take it for years. Nausea, constipation and the other discomforts of the first weeks are gathered in the post on <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-side-effects\/\"><strong>Mounjaro<\/strong> side effects<\/a>. This post covers the long-term side effects (kidneys, liver, heart, pancreas and cancer) and shows how far the studies have gone for each one.<\/p>\n<h2>Is Mounjaro harmful with long-term use?<\/h2>\n<p>In the studies that followed <strong>tirzepatide<\/strong> for up to about four years, <strong>Mounjaro<\/strong> showed no damage to the kidneys, the liver or the heart. In people with type 2 diabetes, it had <strong>fewer serious kidney problems<\/strong> than <strong>dulaglutide<\/strong>, an older injection already shown to protect the heart, and it did no worse than dulaglutide for heart attack, stroke and death from heart disease. In a one-year study, it removed fat and inflammation from the liver. A 2026 review that pooled the controlled studies of the injections in this group found no increase in cancer. The known risks over the course of treatment are dehydration that can injure the kidneys, pancreatitis, gallstones and muscle loss. There are still no data on use over decades and no finished study on the heart in people with obesity but no diabetes.<\/p>\n<h2>How long Mounjaro has been studied<\/h2>\n<p>What counts as long term depends on the question, and a study that wants to know whether a drug protects the heart usually lasts years, because heart attacks and strokes need time to happen in large enough numbers. For cancer, the ideal follow-up would be even longer, since many tumors take years to grow until they are found. The <strong>tirzepatide<\/strong> studies looked at each organ over a different length of time.<\/p>\n<figure class=\"nering-chart\">\n<img decoding=\"async\" src=\"\/blog\/wp-content\/uploads\/mounjaro-longo-prazo-duracao-en.svg\" alt=\"Timeline from 0 to 10 years showing how long each study followed people who took tirzepatide: real-world study comparing it with semaglutide, about 6 months; liver (SYNERGY-NASH), 1 year; cancer review, median of 70 weeks; heart failure (SUMMIT), median of 2 years; obesity (SURMOUNT-1), 3 years; heart and kidneys (SURPASS-CVOT), median of 4 years. From 4 to 10 years the band is empty: there is no study yet.\" width=\"640\" height=\"452\" loading=\"lazy\"><br \/>\n<\/figure>\n<p>The longest study is SURPASS-CVOT, in people who had type 2 diabetes and artery disease. Among people without diabetes, the longest is the extension of one of the first <strong>tirzepatide<\/strong> studies in obesity (SURMOUNT-1), which kept people with obesity and prediabetes on the drug for three years and ended with <strong>no new safety signal<\/strong>. The liver result comes from a one-year study. The SURPASS-CVOT researchers also analyzed the kidneys, and the heart comparison with <strong>semaglutide<\/strong> comes from real-world data from American health plans.<\/p>\n<h2>Does Mounjaro harm the kidneys over time?<\/h2>\n<p>In the longest study done with the drug, <strong>Mounjaro<\/strong> did no harm to the kidneys of people with type 2 diabetes over about four years. The result came out in 2026 in <strong>Lancet Diabetes &amp; Endocrinology<\/strong> (paid for by Eli Lilly). The SURPASS-CVOT researchers looked at the kidneys of the participants, who had artery disease and took either <strong>tirzepatide<\/strong> or <strong>dulaglutide<\/strong>, that older injection from the same <strong>GLP-1<\/strong> group, with proven heart protection. Over this period, the <strong>tirzepatide<\/strong> group had <strong>23% fewer serious kidney problems<\/strong>, counting as a serious problem high albumin in the urine that does not come down, the loss of half or more of the filtration, the need for dialysis and death from kidney disease.<\/p>\n<figure class=\"nering-chart\">\n<img decoding=\"async\" src=\"\/blog\/wp-content\/uploads\/mounjaro-rim-surpass-cvot-en.svg\" alt=\"Bar chart from the SURPASS-CVOT study, kidney analysis published in 2026: over about 4 years, 6.0% of those who took tirzepatide and 7.6% of those who took dulaglutide had a serious kidney problem.\" width=\"640\" height=\"400\" loading=\"lazy\"><br \/>\n<\/figure>\n<p>In people whose kidneys were in better shape, the difference came from fewer people starting to lose a lot of albumin in the urine, and in those who already had high-risk kidney disease, it came from filtration falling more slowly. The researchers planned this analysis from the start, but it was not the main question of the study, and everyone in it had diabetes, so the result does not automatically apply to people who use <strong>Mounjaro<\/strong> only to lose weight. An earlier analysis, from a study that compared <strong>tirzepatide<\/strong> with <strong>insulin<\/strong> (SURPASS-4), pointed in the same direction.<\/p>\n<p>With obesity or diabetes, the kidneys spend years filtering more than they should, start letting albumin (a protein) leak into the urine and, over time, lose filtering capacity. On lab tests, this shows up as <strong>albumin in the urine<\/strong> and as a drop in the filtration rate, which is calculated from blood creatinine. <strong>Tirzepatide<\/strong> lowers glucose, blood pressure and weight, and the likely explanation for its effect on the kidneys is this lighter load.<\/p>\n<p>The first study of this group of drugs designed only for the kidneys was done with <strong>semaglutide<\/strong> (FLOW) and came out in 2024 in the <strong>New England Journal of Medicine<\/strong>. The study committee recommended stopping it earlier than planned, after a look at the data that had already been scheduled halfway through, and it showed that <strong>semaglutide<\/strong> (the substance in <strong>Ozempic<\/strong> and <strong>Wegovy<\/strong>) reduced serious kidney complications in people who had diabetes and kidney disease. <strong>Tirzepatide<\/strong> does not yet have a finished study like that. A smaller study in people with kidney disease, which measured kidney fat and function over one year, ended in July 2026 and its results have not been published yet. Dialysis and death from kidney disease are secondary questions of the large <strong>tirzepatide<\/strong> study in people with obesity without diabetes, due to end in 2027.<\/p>\n<p>The American label lists <strong>acute kidney injury from dehydration<\/strong>, which sometimes requires dialysis. In most cases it appeared in people who had severe nausea, vomiting or diarrhea, and the label asks for extra attention at the start of treatment and during dose increases. People who already have diseased kidneys are at greater risk, because they have less reserve to cope with the lack of water. Even so, the label does not forbid the drug in these cases, and kidney disease does not change the amount of <strong>tirzepatide<\/strong> that stays in the blood, but hydration and lab tests call for extra care.<\/p>\n<h2>Is Mounjaro bad for the liver?<\/h2>\n<p><strong>Tirzepatide<\/strong> showed no liver damage in the studies, and in a one-year study it also removed fat and inflammation from the liver. Fat in the liver, called steatosis, is very common in people with obesity or diabetes. In some of these people the fat inflames the liver (<strong>steatohepatitis<\/strong>), and the inflammation leaves scars, called fibrosis, which over the years can turn into cirrhosis.<\/p>\n<p>The American label does not list liver injury among the warnings for <strong>tirzepatide<\/strong> and says that liver disease does not change the amount of drug that stays in the blood. The researchers looked more at the other side, whether it helps a diseased liver, and the main data come from a study with liver biopsy (SYNERGY-NASH), published in 2024 in the <strong>New England Journal of Medicine<\/strong> (paid for by Eli Lilly). It is a phase 2 study, a smaller stage that tests whether a large study is worth doing.<\/p>\n<p>People with steatohepatitis and fibrosis confirmed by biopsy took <strong>tirzepatide<\/strong> or placebo for one year and repeated the biopsy at the end. The <strong>liver inflammation went away<\/strong>, with no worsening of fibrosis, in up to 6 in 10 people who took the drug, far more than in the placebo group, and fibrosis also improved more often.<\/p>\n<p>I find the result good, but it comes from a small, one-year study, and the authors themselves call for larger and longer studies. <strong>Semaglutide<\/strong> is a step ahead, because a large phase 3 study done with it (ESSENCE), published in 2025 in the <strong>New England Journal of Medicine<\/strong>, led the American drug agency to approve <strong>Wegovy<\/strong> for steatohepatitis with fibrosis in August 2025, in an accelerated approval that still depends on long-term results. Nobody knows yet, for <strong>semaglutide<\/strong> or for <strong>tirzepatide<\/strong>, whether removing fat and inflammation from the liver will prevent cirrhosis, liver cancer or a transplant.<\/p>\n<p>Close to the liver, a known problem for people who lose weight quickly is <strong>gallstones<\/strong>, which I covered when writing about the <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/weight-loss-injections-mounjaro-ozempic\/\">weight-loss injections <strong>Mounjaro<\/strong> and <strong>Ozempic<\/strong><\/a>. They can cause pain on the right side, below the ribs, and turn the eyes yellowish when a stone blocks the bile duct.<\/p>\n<h2>Is Mounjaro bad for the heart?<\/h2>\n<p>In people with diabetes, the heart did well with <strong>Mounjaro<\/strong> in the studies done so far. The label notes a small rise in resting heart rate, of a few beats per minute on average, something that also happens with other injections in the <strong>GLP-1<\/strong> group, and the studies that counted heart attacks and strokes found no more of these problems with <strong>tirzepatide<\/strong>. In SURPASS-CVOT, published in 2025 in the <strong>New England Journal of Medicine<\/strong> (paid for by Eli Lilly), <strong>tirzepatide<\/strong> did no worse than <strong>dulaglutide<\/strong> for heart attack, stroke and death from heart disease over the whole follow-up, in people who had type 2 diabetes and artery disease.<\/p>\n<p>What was missing was a comparison of <strong>tirzepatide<\/strong> with <strong>semaglutide<\/strong>, which has its own heart protection studies. There is no study in which people were randomly assigned to one injection or the other to put the two head to head on this. Researchers from Harvard, in Boston, and the Technical University of Munich tried to fill this gap with data from American health plans, in a paper published in <strong>Nature Medicine<\/strong> (funded by the US National Institutes of Health and the German Heart Foundation, with no manufacturer money). First they reproduced two known randomized studies with these data, to check whether the method reached the same result. Then they compared the two injections in hundreds of thousands of adults with type 2 diabetes and obesity. Over one year, <strong>the risk of heart attack, stroke or death<\/strong> was 1.3% with both.<\/p>\n<p>This work observes people who were already taking the drug, without randomization, and even with statistical adjustments some difference between the groups may remain. Everyone had diabetes, and on average people used the injection for only a few months, which, as the authors themselves warn, does not capture long-term effects. In heart failure, <strong>tirzepatide<\/strong> looked slightly better, without statistical certainty.<\/p>\n<p>In the type of heart failure in which the heart pumps with normal strength, very common in people with obesity, a study in people who have both problems (SUMMIT) showed that <strong>tirzepatide<\/strong> reduced episodes of worsening over about two years, with no proven effect on deaths. I compared the effect of the injections on the heart in detail in the post on <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/which-weight-loss-injection-works-best\/\">which injection leads to more weight loss<\/a>. For people with obesity without diabetes who have already had heart disease, <strong>semaglutide<\/strong> showed protection in a study with more than three years of follow-up (SELECT), and the equivalent <strong>tirzepatide<\/strong> study (SURMOUNT-MMO) is still under way. Until it ends, the heart benefit of <strong>Mounjaro<\/strong> in people without diabetes remains an expectation.<\/p>\n<h2>Does Mounjaro cause cancer or harm the pancreas?<\/h2>\n<p>Pancreatitis is a risk of treatment, rare and sudden in onset, with severe belly pain, and the <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-side-effects\/\">signs of pancreatitis with <strong>Mounjaro<\/strong><\/a> are listed with the other side effects. The long-term fear is usually cancer, and it grew out of two old observations. In rats, drugs in this group caused tumors in the C cells of the thyroid. And, early on, the American adverse event reporting system received more reports of pancreatitis and pancreatic cancer with <strong>exenatide<\/strong>, one of the first injections. Pancreatitis stayed on the label, and the increase in pancreatic cancer was not confirmed in the large studies done later.<\/p>\n<p>The most complete review on this came out in <strong>Annals of Internal Medicine<\/strong>, done without sponsorship. The authors gathered all the placebo-controlled randomized studies of the <strong>GLP-1<\/strong> group injections approved in the United States, including <strong>tirzepatide<\/strong>, and counted the cases of cancers linked to obesity. With moderate-quality evidence, the authors concluded that the injections <strong>probably make little or no difference<\/strong> to the risk of thyroid, pancreatic, breast and kidney cancer. For the bowel, liver, gallbladder, ovary and uterus, the answer was similar, but with weaker evidence, and the result held when they looked only at <strong>semaglutide<\/strong> and <strong>tirzepatide<\/strong>.<\/p>\n<figure class=\"nering-chart\">\n<img decoding=\"async\" src=\"\/blog\/wp-content\/uploads\/mounjaro-cancer-ko-en.svg\" alt=\"Dot chart with intervals from the review published in Annals of Internal Medicine, showing the cancer risk in people who used GLP-1 group injections compared with placebo: thyroid 1.37 (from 0.82 to 2.31), pancreas 0.84 (from 0.53 to 1.35), breast 0.95 (from 0.60 to 1.49) and kidney 1.12 (from 0.78 to 1.60). All the intervals cross the line at 1, which means equal risk: no difference was proven, and the thyroid point, 1.37, is not a proven increase.\" width=\"640\" height=\"400\" loading=\"lazy\"><br \/>\n<\/figure>\n<p>The limit of this review is time, because the studies generally lasted a little over a year, and almost none was designed to look for cancer. The authors noted a trend toward more colorectal cancer in the studies that went beyond three years and more gallbladder cancer with longer treatments, with few cases and wide intervals, and they called for long studies to clarify this. Observational studies usually show less cancer in people who use the injection, but people who take these drugs tend to have better access to health care and better habits, and that skews the math.<\/p>\n<p>As for the thyroid, the label rule still applies: anyone who has or has had medullary thyroid cancer, or has a family history of it, or has the genetic syndrome MEN 2, should not use it. This topic will get a post of its own, with the studies done in people.<\/p>\n<h2>What we know and what we still need to learn<\/h2>\n<table>\n<colgroup>\n<col style=\"width: 33%\" \/>\n<col style=\"width: 33%\" \/>\n<col style=\"width: 33%\" \/>\n<\/colgroup>\n<thead>\n<tr>\n<th>Organ<\/th>\n<th>What the studies show<\/th>\n<th>What we still need to learn<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Kidneys<\/td>\n<td>Fewer serious kidney problems than with <strong>dulaglutide<\/strong>, in people with diabetes, over about 4 years<\/td>\n<td>A dedicated study in kidney disease and data in people without diabetes<\/td>\n<\/tr>\n<tr>\n<td>Liver<\/td>\n<td>Less fat and inflammation in 1 year, in a phase 2 study<\/td>\n<td>Whether it prevents cirrhosis, liver cancer and transplant<\/td>\n<\/tr>\n<tr>\n<td>Heart<\/td>\n<td>Did no worse than an injection that already protects, in people with diabetes<\/td>\n<td>Results in people with obesity without diabetes (study under way)<\/td>\n<\/tr>\n<tr>\n<td>Pancreas<\/td>\n<td>Rare pancreatitis; no increase in pancreatic cancer<\/td>\n<td>Effect after many years of use<\/td>\n<\/tr>\n<tr>\n<td>Cancer in general<\/td>\n<td>No increase in the controlled studies, which generally lasted a little over 1 year<\/td>\n<td>Cancers that take many years to show up<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Care for people who take Mounjaro for years<\/h2>\n<p>Anyone who takes the drug for a long time needs <strong>regular medical follow-up<\/strong>, with visits, weight, blood pressure and blood and urine tests, such as creatinine, urine albumin, glucose and liver enzymes, as often as your doctor decides. These tests show early whether the kidneys or the liver are changing, for better or worse. Body composition also counts, because people who lose a lot of weight lose muscle along with the fat, and a <a href=\"https:\/\/clinicanering.com\/blog\/en\/body-composition\/bioimpedance-what-the-test-shows\/\">bioimpedance test<\/a> helps show what is being lost. Strength training and enough protein reduce this loss, as I explained when I wrote about <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/lose-weight-without-losing-muscle\/\">losing weight without losing muscle<\/a>.<\/p>\n<p>The signs that call for prompt care, such as severe, constant belly pain and <strong>little, dark urine<\/strong> after vomiting or diarrhea, are in the <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-side-effects\/\">table of <strong>Mounjaro<\/strong> warning signs<\/a>. People who take the drug for years should add to that list the signs that appear slowly and deserve a visit: yellowish skin or eyes, which call for a check of the liver and gallbladder; a racing heart at rest, shortness of breath or swollen legs; and a lump in the neck or hoarseness that does not go away.<\/p>\n<h2>In practice<\/h2>\n<ol type=\"1\">\n<li>Talk with your doctor about the idea of taking <strong>Mounjaro<\/strong> for years before you start, since stopping usually brings the weight back.<\/li>\n<li>Get the kidney, liver and glucose tests your doctor orders at the start and throughout treatment.<\/li>\n<li>Drink water through the day and seek care if you have vomiting or diarrhea that won&#8217;t stop.<\/li>\n<li>Tell the team you use the injection before any test with sedation or any surgery, because of the <a href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/weight-loss-injections-mounjaro-ozempic\/\">care needed with anesthesia<\/a> that I explained in the post on the injections.<\/li>\n<li>Do strength training and eat enough protein so you don&#8217;t lose muscle along with the fat.<\/li>\n<li>Buy only the registered drug, with a prescription, because the unregistered version has none of these studies behind it.<\/li>\n<\/ol>\n<h2>Conclusion<\/h2>\n<p>As far as the studies have gone, about four years for the kidneys and the heart and one year for the liver, <strong>Mounjaro<\/strong> did no harm to any of the three, and in people with diabetes it did better for the kidneys and no worse for the heart than an injection already shown to protect it. Gallstones, muscle loss, pancreatitis and dehydration give signs you can notice, and your doctor tracks the rest with lab tests. We still can&#8217;t say what happens after decades of use or whether clearing liver inflammation prevents cirrhosis, and the heart effect in people with obesity without diabetes depends on the large study that is still under way.<\/p>\n<p>All the best!<br \/>\nG<\/p>\n<hr \/>\n<p><strong>Responsible physician:<\/strong> <a href=\"https:\/\/clinicanering.com\/sobre\/\">Dr. Gilberto Nering Junior<\/a>, <a href=\"https:\/\/clinicanering.com\/medicina-do-esporte\/\">sports medicine physician<\/a>, CRM-SP 160822, RQE 142486 (Sports Medicine, Brazil).<\/p>\n<p><small>This text was not sponsored, is for information only and does not replace an individual assessment. Questions about the content: <a href=\"https:\/\/clinicanering.com\/contato\/\">contact the clinic<\/a>.<\/small><\/p>\n<p>Cover photo: Mounjaro pen, Eli Lilly press image, cropped and placed on a studio background.<\/p>\n<div class=\"nering-faq\">\n<h2>Frequently asked questions about Mounjaro in the long term<\/h2>\n<h3>Can people with kidney disease take Mounjaro?<\/h3>\n<p>The label does not forbid use in people with kidney disease, and in people with diabetes tirzepatide had fewer serious kidney problems than dulaglutide, an older injection, in the longest study done with it. The main precaution is to avoid dehydration from vomiting or diarrhea, which can injure the kidneys, and to get the tests your doctor orders.<\/p>\n<h3>Can people with fatty liver take Mounjaro?<\/h3>\n<p>The American label does not forbid use, does not list liver injury among the warnings for tirzepatide and says that liver disease does not change the amount of drug that stays in the blood. In a one-year study, it reduced fat and inflammation in the liver of people with steatohepatitis, but we still don&#8217;t know whether this prevents cirrhosis.<\/p>\n<h3>Does Mounjaro increase the risk of cancer?<\/h3>\n<p>A 2026 review of the controlled studies of the GLP-1 group injections, including tirzepatide, found no increase in thyroid, pancreatic, breast or kidney cancer. The studies were short for cancers that take a long time to show up, and anyone with medullary thyroid cancer or a family history of it should not use it.<\/p>\n<h3>Does Mounjaro protect the heart in people without diabetes?<\/h3>\n<p>We don&#8217;t know yet, because the tirzepatide study in people with obesity without diabetes is still under way. In people with type 2 diabetes and artery disease, it did no worse than an older injection already shown to protect the heart. It also raises the resting heart rate slightly.<\/p>\n<h3>How long can I take Mounjaro?<\/h3>\n<p>There is no set maximum, because obesity is a chronic disease and the weight tends to come back when the drug is stopped. The longest controlled study lasted close to four years, and the length of treatment is decided with your doctor, with visits and tests along the way.<\/p>\n<\/div>\n<h2>References<\/h2>\n<ol type=\"1\">\n<li>Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. <em>Hepatology<\/em>. 2026;83(5):1326-1340. <a href=\"https:\/\/doi.org\/10.1097\/HEP.0000000000001608\">doi:10.1097\/HEP.0000000000001608<\/a><\/li>\n<li>Eli Lilly and Company. Zepbound (tirzepatide) injection: prescribing information. Indianapolis: Eli Lilly; 2026. <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b\">DailyMed<\/a><\/li>\n<li>Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. <em>Lancet Diabetes Endocrinol<\/em>. 2022;10(11):774-785. <a href=\"https:\/\/doi.org\/10.1016\/S2213-8587(22)00243-1\">doi:10.1016\/S2213-8587(22)00243-1<\/a><\/li>\n<li>Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. <em>N Engl J Med<\/em>. 2025;392(10):958-971. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2410819\">doi:10.1056\/NEJMoa2410819<\/a><\/li>\n<li>Ko A, Chang YC, Bahar F, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. <em>Ann Intern Med<\/em>. 2026;179(2):216-229. <a href=\"https:\/\/doi.org\/10.7326\/ANNALS-25-02237\">doi:10.7326\/ANNALS-25-02237<\/a><\/li>\n<li>Kr\u00fcger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. <em>Nat Med<\/em>. 2026;32(1):342-352. <a href=\"https:\/\/doi.org\/10.1038\/s41591-025-04102-x\">doi:10.1038\/s41591-025-04102-x<\/a><\/li>\n<li>Lam CSP, Rodriguez A, Aminian A, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. <em>Obesity (Silver Spring)<\/em>. 2025;33(9):1645-1656. <a href=\"https:\/\/doi.org\/10.1002\/oby.24332\">doi:10.1002\/oby.24332<\/a><\/li>\n<li>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. <em>N Engl J Med<\/em>. 2023;389(24):2221-2232. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\">doi:10.1056\/NEJMoa2307563<\/a><\/li>\n<li>Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. <em>N Engl J Med<\/em>. 2024;391(4):299-310. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2401943\">doi:10.1056\/NEJMoa2401943<\/a><\/li>\n<li>Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. <em>N Engl J Med<\/em>. 2025;393(24):2409-2420. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2505928\">doi:10.1056\/NEJMoa2505928<\/a><\/li>\n<li>Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. <em>N Engl J Med<\/em>. 2025;392(5):427-437. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2410027\">doi:10.1056\/NEJMoa2410027<\/a><\/li>\n<li>Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. <em>N Engl J Med<\/em>. 2024;391(2):109-121. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2403347\">doi:10.1056\/NEJMoa2403347<\/a><\/li>\n<li>Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. <em>N Engl J Med<\/em>. 2025;392(21):2089-2099. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2413258\">doi:10.1056\/NEJMoa2413258<\/a><\/li>\n<li>U.S. Food and Drug Administration. Drugs@FDA: Mounjaro (tirzepatide), NDA 215866. Silver Spring: FDA; 2022. <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=215866\">Drugs@FDA<\/a><\/li>\n<li>Zoungas S, D\u2019Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. <em>Lancet Diabetes Endocrinol<\/em>. 2026;14(7):544-557. <a href=\"https:\/\/doi.org\/10.1016\/S2213-8587(26)00032-X\">doi:10.1016\/S2213-8587(26)00032-X<\/a><\/li>\n<\/ol>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"inLanguage\": \"en\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"Can people with kidney disease take Mounjaro?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"The label does not forbid use in people with kidney disease, and in people with diabetes tirzepatide had fewer serious kidney problems than dulaglutide, an older injection, in the longest study done with it. The main precaution is to avoid dehydration from vomiting or diarrhea, which can injure the kidneys, and to get the tests your doctor orders.\"}}, {\"@type\": \"Question\", \"name\": \"Can people with fatty liver take Mounjaro?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"The American label does not forbid use, does not list liver injury among the warnings for tirzepatide and says that liver disease does not change the amount of drug that stays in the blood. In a one-year study, it reduced fat and inflammation in the liver of people with steatohepatitis, but we still don't know whether this prevents cirrhosis.\"}}, {\"@type\": \"Question\", \"name\": \"Does Mounjaro increase the risk of cancer?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"A 2026 review of the controlled studies of the GLP-1 group injections, including tirzepatide, found no increase in thyroid, pancreatic, breast or kidney cancer. The studies were short for cancers that take a long time to show up, and anyone with medullary thyroid cancer or a family history of it should not use it.\"}}, {\"@type\": \"Question\", \"name\": \"Does Mounjaro protect the heart in people without diabetes?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"We don't know yet, because the tirzepatide study in people with obesity without diabetes is still under way. In people with type 2 diabetes and artery disease, it did no worse than an older injection already shown to protect the heart. It also raises the resting heart rate slightly.\"}}, {\"@type\": \"Question\", \"name\": \"How long can I take Mounjaro?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"There is no set maximum, because obesity is a chronic disease and the weight tends to come back when the drug is stopped. The longest controlled study lasted close to four years, and the length of treatment is decided with your doctor, with visits and tests along the way.\"}}]}<\/script><\/p>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"Organization\", \"@id\": \"https:\/\/clinicanering.com\/#org\", \"name\": \"Cl\u00ednica Nering\", \"url\": \"https:\/\/clinicanering.com\"}, {\"@type\": \"Person\", \"@id\": \"https:\/\/clinicanering.com\/#dr-gilberto\", \"name\": \"Dr. Gilberto Nering Junior\", \"jobTitle\": \"Sports Medicine Physician\", \"identifier\": \"CRM-SP 160822 \/ RQE 142486\", \"worksFor\": {\"@id\": \"https:\/\/clinicanering.com\/#org\"}, \"sameAs\": [\"https:\/\/www.doctoralia.com.br\/gilberto-nering-junior\", \"https:\/\/www.instagram.com\/clinica.nering\"]}, {\"@type\": \"MedicalWebPage\", \"@id\": \"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#webpage\", \"url\": \"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/\", \"name\": \"Is Mounjaro safe long term? Kidneys, liver and heart\", \"inLanguage\": \"en\", \"datePublished\": \"2026-11-15T02:22:51+00:00\", \"dateModified\": \"2026-11-15T02:22:51+00:00\", \"author\": {\"@id\": \"https:\/\/clinicanering.com\/#dr-gilberto\"}, \"reviewedBy\": {\"@id\": \"https:\/\/clinicanering.com\/#dr-gilberto\"}, \"publisher\": {\"@id\": \"https:\/\/clinicanering.com\/#org\"}, \"isPartOf\": {\"@type\": \"WebSite\", \"name\": \"Cl\u00ednica Nering Blog\", \"url\": \"https:\/\/clinicanering.com\/blog\/\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.<\/p>\n","protected":false},"author":1,"featured_media":2734,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[],"class_list":["post-2906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss","entry entry-center"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Is Mounjaro safe long term? Kidneys, liver and heart<\/title>\n<meta name=\"description\" content=\"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Mounjaro safe long term? Kidneys, liver and heart\" \/>\n<meta property=\"og:description\" content=\"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog Cl\u00ednica Nering\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-15T02:22:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"840\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Dr. Gilberto Nering Junior\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Gilberto Nering Junior\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"18 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/\"},\"author\":{\"name\":\"Dr. Gilberto Nering Junior\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#\\\/schema\\\/person\\\/7ad6b0ae64865ab53b092185769b59d3\"},\"headline\":\"Is Mounjaro safe long term? Kidneys, liver and heart\",\"datePublished\":\"2026-11-15T02:22:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/\"},\"wordCount\":3709,\"publisher\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/wp-content\\\/uploads\\\/mounjaro-faz-mal-longo-prazo-capa.webp\",\"articleSection\":[\"Weight Loss\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/\",\"url\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/\",\"name\":\"Is Mounjaro safe long term? Kidneys, liver and heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/wp-content\\\/uploads\\\/mounjaro-faz-mal-longo-prazo-capa.webp\",\"datePublished\":\"2026-11-15T02:22:51+00:00\",\"description\":\"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/wp-content\\\/uploads\\\/mounjaro-faz-mal-longo-prazo-capa.webp\",\"contentUrl\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/wp-content\\\/uploads\\\/mounjaro-faz-mal-longo-prazo-capa.webp\",\"width\":1600,\"height\":840,\"caption\":\"Caneta de dose \u00fanica do Mounjaro na diagonal, com o r\u00f3tulo e a marca \u00e0 vista, sobre fundo ameixa de est\u00fadio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/en\\\/weight-loss\\\/mounjaro-long-term-safety\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Mounjaro safe long term? Kidneys, liver and heart\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/\",\"name\":\"Cl\u00ednica Nering\",\"description\":\"Performance e Sa\u00fade\",\"publisher\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#organization\",\"name\":\"Cl\u00ednica Nering\",\"url\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blog.clinicanering.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Design-sem-nome.png\",\"contentUrl\":\"https:\\\/\\\/blog.clinicanering.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Design-sem-nome.png\",\"width\":1563,\"height\":1563,\"caption\":\"Cl\u00ednica Nering\"},\"image\":{\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/clinica.nering\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/#\\\/schema\\\/person\\\/7ad6b0ae64865ab53b092185769b59d3\",\"name\":\"Dr. Gilberto Nering Junior\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/clinicanering.com\\\/wp-content\\\/themes\\\/Clinica%20Nering\\\/assets\\\/images\\\/relume-254303-p-800.jpeg\",\"url\":\"https:\\\/\\\/clinicanering.com\\\/wp-content\\\/themes\\\/Clinica%20Nering\\\/assets\\\/images\\\/relume-254303-p-800.jpeg\",\"contentUrl\":\"https:\\\/\\\/clinicanering.com\\\/wp-content\\\/themes\\\/Clinica%20Nering\\\/assets\\\/images\\\/relume-254303-p-800.jpeg\",\"caption\":\"Dr. Gilberto Nering Junior\"},\"description\":\"M\u00e9dico do Esporte, Nutr\u00f3logo. Especialista em performance, emagrecimento e sa\u00fade metab\u00f3lica. Autor de \u201cO Guia Completo de Beach Tennis\u201d.\",\"sameAs\":[\"https:\\\/\\\/blog.clinicanering.com\"],\"url\":\"https:\\\/\\\/clinicanering.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is Mounjaro safe long term? Kidneys, liver and heart","description":"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/","og_locale":"pt_PT","og_type":"article","og_title":"Is Mounjaro safe long term? Kidneys, liver and heart","og_description":"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.","og_url":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/","og_site_name":"Blog Cl\u00ednica Nering","article_published_time":"2026-11-15T02:22:51+00:00","og_image":[{"width":1600,"height":840,"url":"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp","type":"image\/webp"}],"author":"Dr. Gilberto Nering Junior","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Dr. Gilberto Nering Junior","Tempo estimado de leitura":"18 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#article","isPartOf":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/"},"author":{"name":"Dr. Gilberto Nering Junior","@id":"https:\/\/clinicanering.com\/blog\/#\/schema\/person\/7ad6b0ae64865ab53b092185769b59d3"},"headline":"Is Mounjaro safe long term? Kidneys, liver and heart","datePublished":"2026-11-15T02:22:51+00:00","mainEntityOfPage":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/"},"wordCount":3709,"publisher":{"@id":"https:\/\/clinicanering.com\/blog\/#organization"},"image":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#primaryimage"},"thumbnailUrl":"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp","articleSection":["Weight Loss"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/","url":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/","name":"Is Mounjaro safe long term? Kidneys, liver and heart","isPartOf":{"@id":"https:\/\/clinicanering.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#primaryimage"},"image":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#primaryimage"},"thumbnailUrl":"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp","datePublished":"2026-11-15T02:22:51+00:00","description":"In studies of about 4 years for the kidneys and heart and 1 year for the liver, Mounjaro did no harm. What happens after decades is still unknown.","breadcrumb":{"@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#primaryimage","url":"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp","contentUrl":"https:\/\/clinicanering.com\/blog\/wp-content\/uploads\/mounjaro-faz-mal-longo-prazo-capa.webp","width":1600,"height":840,"caption":"Caneta de dose \u00fanica do Mounjaro na diagonal, com o r\u00f3tulo e a marca \u00e0 vista, sobre fundo ameixa de est\u00fadio"},{"@type":"BreadcrumbList","@id":"https:\/\/clinicanering.com\/blog\/en\/weight-loss\/mounjaro-long-term-safety\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/clinicanering.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Is Mounjaro safe long term? Kidneys, liver and heart"}]},{"@type":"WebSite","@id":"https:\/\/clinicanering.com\/blog\/#website","url":"https:\/\/clinicanering.com\/blog\/","name":"Cl\u00ednica Nering","description":"Performance e Sa\u00fade","publisher":{"@id":"https:\/\/clinicanering.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinicanering.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/clinicanering.com\/blog\/#organization","name":"Cl\u00ednica Nering","url":"https:\/\/clinicanering.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/clinicanering.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/blog.clinicanering.com\/wp-content\/uploads\/2025\/08\/Design-sem-nome.png","contentUrl":"https:\/\/blog.clinicanering.com\/wp-content\/uploads\/2025\/08\/Design-sem-nome.png","width":1563,"height":1563,"caption":"Cl\u00ednica Nering"},"image":{"@id":"https:\/\/clinicanering.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/clinica.nering"]},{"@type":"Person","@id":"https:\/\/clinicanering.com\/blog\/#\/schema\/person\/7ad6b0ae64865ab53b092185769b59d3","name":"Dr. Gilberto Nering Junior","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/clinicanering.com\/wp-content\/themes\/Clinica%20Nering\/assets\/images\/relume-254303-p-800.jpeg","url":"https:\/\/clinicanering.com\/wp-content\/themes\/Clinica%20Nering\/assets\/images\/relume-254303-p-800.jpeg","contentUrl":"https:\/\/clinicanering.com\/wp-content\/themes\/Clinica%20Nering\/assets\/images\/relume-254303-p-800.jpeg","caption":"Dr. Gilberto Nering Junior"},"description":"M\u00e9dico do Esporte, Nutr\u00f3logo. Especialista em performance, emagrecimento e sa\u00fade metab\u00f3lica. Autor de \u201cO Guia Completo de Beach Tennis\u201d.","sameAs":["https:\/\/blog.clinicanering.com"],"url":"https:\/\/clinicanering.com\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/posts\/2906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/comments?post=2906"}],"version-history":[{"count":1,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/posts\/2906\/revisions"}],"predecessor-version":[{"id":2907,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/posts\/2906\/revisions\/2907"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/media\/2734"}],"wp:attachment":[{"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/media?parent=2906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/categories?post=2906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinicanering.com\/blog\/wp-json\/wp\/v2\/tags?post=2906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}